TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2590625

Group type: EXPERIMENTAL
Intervention: Coal tar gel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Topical corticosteroid
Number of subjects: 45
Study: 5473608

Group type: EXPERIMENTAL
Intervention: Electrolyte solution containing both glucose and glycine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrolyte solution containing glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrolyte solution containing glycine
Number of subjects: 0
Study: 30798376

Group type: EXPERIMENTAL
Intervention: PMTCT intervention with male partner involvement
Number of subjects: 1370

Group type: COMPARATOR
Intervention: PMTCT intervention without male partner involvement
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1370
Study: 31200633

Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study: 29236273

Group type: EXPERIMENTAL
Intervention: Auditory brainstem response (ABR) presence
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: No recorded wave of ABR
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Distortion‐product OAE (DP‐OAE)
Number of subjects: 60
Study: 25481673

Group type: EXPERIMENTAL
Intervention: FOLFIRI-B (bevacizumab plus FOLFIRI)
Number of subjects: 142

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 142
Study: 24247812

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 200 mg once daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Metoprolol IR 50 mg four times daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Metoprolol IR 100 mg twice daily
Number of subjects: 27
Study: 21926663

Group type: EXPERIMENTAL
Intervention: Washed red blood cells and platelets transfusion
Number of subjects: 162

Group type: COMPARATOR
Intervention: Unwashed red blood cells and platelets transfusion
Number of subjects: 162
Study: 19953917

Group type: EXPERIMENTAL
Intervention: ProSeal‐LMA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal endotracheal tube
Number of subjects: 60
Study: 17296533

Group type: EXPERIMENTAL
Intervention: Steatosis scores of 0-2 among nondiabetic patients
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Steatosis scores of 3-4 among nondiabetic patients
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Steatosis scores of 2-4 among nondiabetic patients
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Steatosis scores among diabetic patients
Number of subjects: 1143
Study: 15131684

Group type: EXPERIMENTAL
Intervention: Laser biometry
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ultrasound biometry
Number of subjects: 39
Study: 11413739

Group type: EXPERIMENTAL
Intervention: Azelastine (1.12 mg/day) nasal spray administered twice daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: Levocabastine (0.4 mg/day) nasal spray administered twice daily
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Levocabastine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Azelastine and Levocabastine
Number of subjects: 180
Study: 9438892

Group type: EXPERIMENTAL
Intervention: Hemodilution combined with induced hypotension (Group 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard management of blood volume and pressure (Group 2)
Number of subjects: 16
Study: 8273195

Group type: EXPERIMENTAL
Intervention: Low-power laser therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3121335

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 91

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 91
Study: 31714844

Group type: EXPERIMENTAL
Intervention: 1-day invitation period
Number of subjects: 201

Group type: COMPARATOR
Intervention: 3-day invitation period
Number of subjects: 201
Study: 30575346

Group type: EXPERIMENTAL
Intervention: Photopheresis with standard immunosuppression therapy (tacrolimus, mycophenolate, prednisone) for 10-15 sessions during the first 6 months after transplantation.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard immunosuppression therapy (tacrolimus, mycophenolate, prednisone) without photopheresis.
Number of subjects: 60
Study: 27267951

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Sham negative ion generator (placebo)
Number of subjects: 95
Study: 25671664

Group type: EXPERIMENTAL
Intervention: Indigenous profile
Number of subjects: 351

Group type: COMPARATOR
Intervention: Mestizo profile
Number of subjects: 351
Study: 23926253

Group type: EXPERIMENTAL
Intervention: Cabergoline (selective D2/D3 agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20622414

Group type: EXPERIMENTAL
Intervention: Various tobacco cessation interventions (specific details not provided)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (Arm 4)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Health education and behavioral therapy (not specified if part of the intervention arms)
Number of subjects: 646
Study: 19301517

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/fluoride dentifrice (0.3% triclosan/2.0% PVM/MA copolymer/0.243% sodium fluoride in a 17% dual silica base)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fluoride dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 81
Study: 16467064

Group type: EXPERIMENTAL
Intervention: Sixteen‐multidetector row computed tomography (MDCT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 50
Study: 14763194

Group type: EXPERIMENTAL
Intervention: Quinacrine pellets (252 mg total, 36 mg per pellet, three applications)
Number of subjects: 180
Study: 10944481

Group type: COMPARATOR
Intervention: Vitamin A (VA) intervention - 16,700 IU weekly
Number of subjects: 293

Group type: COMPARATOR
Intervention: Vitamin A (VA) intervention - 200,000 IU
Number of subjects: 293

Group type: COMPARATOR
Intervention: Vitamin A (VA) on admission (31 infants)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Vitamin A (VA) on discharge (32 infants)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 293
Study: 9501691

Group type: EXPERIMENTAL
Intervention: MNA + MA
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA) and Adrenaline (A)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Vanillylmandelic acid (VMA)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Dopamine (DA)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: DOPA
Number of subjects: 155
Study: 8117509

Group type: EXPERIMENTAL
Intervention: Osteosynthesis (DHS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Primary hemiarthroplasty (HA)
Number of subjects: 43
Study: 2940938

Group type: EXPERIMENTAL
Intervention: Midazolam (0.82 mg/kg) plus Ketamine (2.0 mg/kg i.m.)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Diazepam (not specified dosage) plus Ketamine (2.0 mg/kg i.m.)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ketamine (2.4 mg/kg i.m. alone)
Number of subjects: 69
Study: 31558380

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including educational in-service, evidence-based tools for assessing neuropsychiatric symptoms, and monthly interprofessional team meetings
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 10
Study: 30589048

Group type: EXPERIMENTAL
Intervention: Chronomodulated chemotherapy (CC group) with cisplatin at 80 mg/m2 from 10:00 to 22:00 and 5-fluorouracil (5-FU) at 1000 mg/m2 plus citrovorum factor at 200 mg/m2 from 22:00 to 10:00 for 3 days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine chemotherapy (RC group) with cisplatin infusion within 1 h and 5-FU infusion for about 24 h, same dosage as CC group.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chronomodulated chemotherapy (CC group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine chemotherapy (RC group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 27861157

Group type: EXPERIMENTAL
Intervention: PCR-B (pentostatin, cyclophosphamide, rituximab with bevacizumab)
Number of subjects: 65
Study: 25161021

Group type: EXPERIMENTAL
Intervention: Meropenem 1000mg, 30-minute infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Meropenem 500mg, 3-hour infusion
Number of subjects: 10
Study: 22403209

Group type: EXPERIMENTAL
Intervention: Integrating a physical activity counselor (PAC) into primary health care teams
Number of subjects: 120
Study: 20345421

Group type: EXPERIMENTAL
Intervention: Deep anaesthesia with target-controlled remifentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Normal anaesthesia with target-controlled remifentanil
Number of subjects: 30
Study: 18759607

Group type: EXPERIMENTAL
Intervention: Codman Hakim regular
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miethke ProGAV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Codman Hakim with SiphonGuard
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medtronic Strata
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sophysa Sophy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sophysa Polaris
Number of subjects: 0
Study: 15904635

Group type: EXPERIMENTAL
Intervention: Rosuvastatin at 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin, pravastatin, and simvastatin
Number of subjects: 0
Study: 11689983

Group type: EXPERIMENTAL
Intervention: Knowledge of Results (KR) group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: No Knowledge of Results (NKR) group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 9728642

Group type: EXPERIMENTAL
Intervention: Paroxetine (initially 20 mg, flexible dosing up to 50 mg/d)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo (matching-image placebo)
Number of subjects: 187
Study: 8086867

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins
Number of subjects: 2045

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2045
Study: 2660973

Group type: EXPERIMENTAL
Intervention: Neomycin-Erythromycin (N-E)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Erythromycin-Metronidazole (E-M)
Number of subjects: 125
Study: 8158888

Group type: EXPERIMENTAL
Intervention: Protein-restricted diet (0.4 g per kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibition
Number of subjects: 0
Study: 759617

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.7 microgram/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.4 microgram/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alphaprodine 0.135 mg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alphaprodine 0.270 mg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Meperidine 0.564 mg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Meperidine 1.127 mg/kg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alphaprodine
Number of subjects: 5
Study: 31304562

Group type: EXPERIMENTAL
Intervention: Media Aware Parent (intervention)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Active control (online access to medically-accurate information on adolescent sexual health)
Number of subjects: 355
Study: 28914251

Group type: EXPERIMENTAL
Intervention: Platelet‐rich fibrin (PRF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 50
Study: 26069259

Group type: EXPERIMENTAL
Intervention: Interactive Intervention (II)
Number of subjects: 1193

Group type: COMPARATOR
Intervention: Enhanced Educational (EE)
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Both groups (II and EE)
Number of subjects: 1193
Study: 24511708

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg day(‐1))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU day(‐1))
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 21511150

Group type: EXPERIMENTAL
Intervention: Preoperative counseling
Number of subjects: 851
Study: 21483189

Group type: EXPERIMENTAL
Intervention: Chest tube removal at 200 ml/day (trial group)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Chest tube removal at 150 ml/day (control group)
Number of subjects: 138
Study: 17524938

Group type: EXPERIMENTAL
Intervention: Cyclosporine 2-hour postdose (C2) levels
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Cyclosporine trough (C0) levels
Number of subjects: 215
Study: 15208500

Group type: EXPERIMENTAL
Intervention: GCPET
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 25
Study: 11434169

Group type: EXPERIMENTAL
Intervention: Children with glomerulonephritis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (Wilm's tumour)
Number of subjects: 16
Study: 9596205

Group type: EXPERIMENTAL
Intervention: DZP rectal gel (15 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous DZP (7.5 mg)
Number of subjects: 20
Study: 7850397

Group type: EXPERIMENTAL
Intervention: True electroconvulsive therapy (ECT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham ECT
Number of subjects: 30
Study: 3241216

Group type: EXPERIMENTAL
Intervention: 5HT (1 ng/kg per min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Acetylcholine (500 ng/kg per min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ICS 205‐930 (700 ng/kg per min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atropine (100 ng/kg per min)
Number of subjects: 7
Study: 30898114

Group type: EXPERIMENTAL
Intervention: Telephone-based aftercare groups (6 sessions over 6 months)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Telephone-based aftercare groups
Number of subjects: 206

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 206
Study: 29188900

Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Training (ART) + fortified milk
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) + fortified milk
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (RT)
Number of subjects: 56
Study: 25319146

Group type: EXPERIMENTAL
Intervention: Corner Osteotomy (CO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pedicle Subtraction Osteotomy (PSO)
Number of subjects: 30
Study: 22972399

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-dose atorvastatin (10 mg)
Number of subjects: 18
Study: 21262890

Group type: EXPERIMENTAL
Intervention: Parenting skills plus healthy lifestyle group (n = 85)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Healthy lifestyle-only group (n = 84)
Number of subjects: 169
Study: 19223428

Group type: EXPERIMENTAL
Intervention: Low-level muscle activity during the 1-h (18)F-FDG uptake phase
Number of subjects: 20

Group type: COMPARATOR
Intervention: No low-level muscle activity (control group)
Number of subjects: 20
Study: 16289241

Group type: EXPERIMENTAL
Intervention: Maternal adipose tissue levels of OC p,p'‐DDE
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Breast milk levels of p,p'‐DDE, dieldrin, and HCB
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Adipose tissue levels of OC metabolites
Number of subjects: 31
Study: 14684710

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 134
Study: 11571237

Group type: EXPERIMENTAL
Intervention: ALT‐711 (210 mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 9609905

Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 41
Study: 8112194

Group type: EXPERIMENTAL
Intervention: Weight-management diet
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High-carbohydrate/fiber diet
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Modified-lipid diet
Number of subjects: 70
Study: 2647022

Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 56

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ultrasound, radioisotope, CT imaging, inspection and palpation at laparotomy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Imaging techniques (ultrasound, radioisotope, CT)
Number of subjects: 56
Study: 31244367

Group type: EXPERIMENTAL
Intervention: Enteral formulas with high GI (Nutrienteral 1.5®, Novasource GI Control®, Diamax®, Isosource Soya®)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enteral formulas with intermediate GI (Fresubin 1.2 HP Fibre®, Nutrison Energy Multifiber 1.5®)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enteral formulas with low GI (Trophic 1.5®, Glucerna®, Novasource GC HP®)
Number of subjects: 40
Study: 31045289

Group type: EXPERIMENTAL
Intervention: Low-frequency ventilation (LFV)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both lungs left collapsed (control)
Number of subjects: 37
Study: 28129714

Group type: EXPERIMENTAL
Intervention: Vardenafil ODT
Number of subjects: 118
Study: 25385203

Group type: EXPERIMENTAL
Intervention: Police-patrolled walking plus social marketing
Number of subjects: 434

Group type: COMPARATOR
Intervention: Police-patrolled walking-only
Number of subjects: 434

Group type: COMPARATOR
Intervention: No-walking intervention
Number of subjects: 434
Study: 23998657

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 190
Study: 21410446

Group type: EXPERIMENTAL
Intervention: Number of drugs added to a participant's medication regimen during the 1‐year study period
Number of subjects: 377

Group type: COMPARATOR
Intervention: Geriatric conditions and functional status (IADL function, cognitive impairment, depression, visual impairment, incontinence, constipation, history of falls or gait instability)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 377
Study: 19628217

Group type: EXPERIMENTAL
Intervention: T‐cell receptor excision circles (TRECs) quantification using neonatal Guthrie cards
Number of subjects: 489
Study: 17364230

Group type: EXPERIMENTAL
Intervention: Alcoholic drinks (target blood alcohol level = .08%)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-alcoholic drinks
Number of subjects: 42
Study: 15377745

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Amesergide (AMSG)
Number of subjects: 19
Study: 11794416

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reading attention control
Number of subjects: 20
Study: 9322808

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/d)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 8454796

Group type: EXPERIMENTAL
Intervention: Solidified benzyl benzoate and tenside agents (A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23
Study: 3961072

Group type: EXPERIMENTAL
Intervention: Alcohol group, drinking .08 ml of pure alcohol per kg body weight
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group, drinking only tonic
Number of subjects: 40
Study: 28805094

Group type: EXPERIMENTAL
Intervention: Balance task-specific training
Number of subjects: 52

Group type: COMPARATOR
Intervention: General physiotherapy (control)
Number of subjects: 52
Study: 27090275

Group type: EXPERIMENTAL
Intervention: Surgi shield (8% carboxymethyl chitosan)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 33
Study: 25115420

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HYS)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Lactated Ringers (LAR)
Number of subjects: 264
Study: 22254230

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) + enamel matrix derivative (EMD)
Number of subjects: 10
Study: 20925534

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 3761

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3761
Study: 18574364

Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg b.i.d. from day 1 to 3, 300 mg q.i.d. from day 4 to 6, and 600 mg t.i.d. from day 7 to 10)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 13
Study: 15906167

Group type: EXPERIMENTAL
Intervention: Talinolol in fast-disintegrating capsules with food
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Talinolol in enteric-coated capsules
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Talinolol in rectal capsules
Number of subjects: 8

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 8
Study: 12641984

Group type: EXPERIMENTAL
Intervention: Glutamine dipeptide (0.5 g/kg/day, orally in bolus)
Number of subjects: 30
Study: 10426876

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary stent implantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IIb-IIIa platelet receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical thrombolysis or thrombectomy devices
Number of subjects: 0
Study: 8924442

Group type: EXPERIMENTAL
Intervention: Violence prevention curriculum taught by the teacher with trained peer leaders
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Violence prevention curriculum taught by the teacher without trained peer leaders
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 223
Study: 1520545

Group type: EXPERIMENTAL
Intervention: Plantago ovata (PO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6542371

Group type: EXPERIMENTAL
Intervention: Thymic factor thymostimulin (TS; Tp‐1 Serono)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 37